Startup making Cas9 proxy for gene editing gets $55M to develop tools/software
Boulder-based startup Inscripta — which you might remember as the company that discovered a new CRISPR enzyme… and then gave it away for free — just landed $55.5 million in a Series C round.
Inscripta made headlines last December when it announced the company had unearthed what its calling “MAD7,” an alternative enzyme to CAS9 that could be used to edit DNA. Having a proxy for Cas9 can get more companies jumping into the gene editing game, Inscripta’s CEO Kevin Ness tells me.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.